Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation - PubMed (original) (raw)

Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation

J I Cohen et al. J Virol. 1991 May.

Abstract

Epstein-Barr virus (EBV) nuclear protein 2 (EBNA-2) is essential for B-lymphocyte growth transformation. EBNA-2 transactivates expression of the EBV latent membrane protein (LMP-1) and also transactivates expression of the B-lymphocyte proteins CD21 and CD23. In order to analyze the functional domains of EBNA-2, we constructed 11 linker-insertion and 15 deletion mutations. Each of the mutant EBNA-2 proteins localized to the nucleus, and each was expressed at levels similar to wild-type EBNA-2. Deletion of both EBNA-2 basic domains was required to prevent nuclear localization, indicating that either is sufficient for nuclear translocation. The mutant EBNA-2 genes were assayed for lymphocyte transformation after recombination with the EBNA-2-deleted P3HR-1 EBV genome and for LMP-1 transactivation following transfection into P3HR-1-infected B-lymphoma cells. Cell lines transformed by recombinant EBV carrying EBNA-2 mutations were assayed for growth properties and LMP-1, CD21, and CD23 expression. The mutational analysis indicates that at least four separate EBNA-2 domains are essential for lymphocyte transformation. Two other domains are necessary for the full transforming phenotype. Two deletion and eight linker-insertion mutations did not reduce transforming activity. Mutations which diminish or abolish lymphocyte transformation also diminish or abolish LMP-1 transactivation, respectively. Cells transformed by recombinant EBV carrying EBNA-2 genes with diminished or normal transforming activity all expressed high levels of LMP-1, CD23, and CD21. These findings suggest that transactivation of these viral and cellular genes by EBNA-2 plays a critical role in lymphocyte transformation by EBV. Furthermore, these results indicate that the transformation and transactivation functions of EBNA-2 may not be separable.

PubMed Disclaimer

Similar articles

• Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
  Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E. Wang F, et al. J Virol. 1990 May;64(5):2309-18. doi: 10.1128/JVI.64.5.2309-2318.1990. J Virol. 1990. PMID: 2157887 Free PMC article.
• Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element.
  Wang F, Kikutani H, Tsang SF, Kishimoto T, Kieff E. Wang F, et al. J Virol. 1991 Aug;65(8):4101-6. doi: 10.1128/JVI.65.8.4101-4106.1991. J Virol. 1991. PMID: 1649318 Free PMC article.
• Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
  Cordier M, Calender A, Billaud M, Zimber U, Rousselet G, Pavlish O, Banchereau J, Tursz T, Bornkamm G, Lenoir GM. Cordier M, et al. J Virol. 1990 Mar;64(3):1002-13. doi: 10.1128/JVI.64.3.1002-1013.1990. J Virol. 1990. PMID: 2154588 Free PMC article.
• Immortalizing genes of Epstein-Barr virus.
  Middleton T, Gahn TA, Martin JM, Sugden B. Middleton T, et al. Adv Virus Res. 1991;40:19-55. doi: 10.1016/s0065-3527(08)60276-6. Adv Virus Res. 1991. PMID: 1659776 Review.
• Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1.
  Kis LL, Takahara M, Nagy N, Klein G, Klein E. Kis LL, et al. Immunol Lett. 2006 Apr 15;104(1-2):83-8. doi: 10.1016/j.imlet.2005.11.003. Epub 2005 Dec 1. Immunol Lett. 2006. PMID: 16386314 Review.

Cited by

• Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression.
  Tsang SF, Wang F, Izumi KM, Kieff E. Tsang SF, et al. J Virol. 1991 Dec;65(12):6765-71. doi: 10.1128/JVI.65.12.6765-6771.1991. J Virol. 1991. PMID: 1658373 Free PMC article.
• Molecular basis for Epstein-Barr virus induced pathogenesis and disease.
  Sample C, Kieff E. Sample C, et al. Springer Semin Immunopathol. 1991;13(2):133-46. doi: 10.1007/BF00201464. Springer Semin Immunopathol. 1991. PMID: 1664982 Review. No abstract available.
• The EBNA2 polyproline region is dispensable for Epstein-Barr virus-mediated immortalization maintenance.
  Gordadze AV, Poston D, Ling PD. Gordadze AV, et al. J Virol. 2002 Jul;76(14):7349-55. doi: 10.1128/jvi.76.14.7349-7355.2002. J Virol. 2002. PMID: 12072534 Free PMC article.
• Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge.
  Sashihara J, Hoshino Y, Bowman JJ, Krogmann T, Burbelo PD, Coffield VM, Kamrud K, Cohen JI. Sashihara J, et al. PLoS Pathog. 2011 Oct;7(10):e1002308. doi: 10.1371/journal.ppat.1002308. Epub 2011 Oct 20. PLoS Pathog. 2011. PMID: 22028652 Free PMC article.
• Identification of a short amino acid sequence essential for efficient nuclear targeting of the Epstein-Barr virus nuclear antigen 3A.
  Le Roux A, Berebbi M, Moukaddem M, Perricaudet M, Joab I. Le Roux A, et al. J Virol. 1993 Mar;67(3):1716-20. doi: 10.1128/JVI.67.3.1716-1720.1993. J Virol. 1993. PMID: 8382317 Free PMC article.

References

1. 1. Nature. 1989 Aug 3;340(6232):393-7 - PubMed
2. 1. J Virol. 1986 Aug;59(2):453-62 - PubMed
3. 1. Cell. 1988 Jul 15;54(2):275-83 - PubMed
4. 1. Oncogene. 1988 May;2(5):461-7 - PubMed
5. 1. J Virol. 1988 Nov;62(11):4173-84 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central